Dec 15, 2025
Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., (Arthrosi) has entered into a definitive agreement to be acquired by Sobi® (STO:SOBI). The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi's pipeline by adding a potentially best-in-class URAT1 inhibitor for patients sub-optimally treated with first-line therapies. Today's announcement reflects Sobi's commitment to advancing treatment options for people living with gout.
Read MoreOct 14, 2025
Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Gout
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced the closing of its $153 million Series E financing led by Prime Eight Capital Limited and with participation from CR Biotech,HighLight Capital, HM Venture Partners, , ReliantTech Limited and existing shareholders.
Read MoreAug 21, 2025
Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced the completion of patient enrollment in its second pivotal global Phase 3 trial, REDUCE 1, evaluating pozdeutinurad (formerly AR882) for the reduction of sUA and tophi in gout and tophaceous gout patients.
Read MoreJul 11, 2025
Arthrosi Announces Multiple Presentations at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced the acceptance of two presentations at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025 meeting, being held June 11-14, 2025, in Barcelona, Spain.
Read MoreJul 11, 2025
Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Replicate Pivotal Phase 3 REDUCE 1 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced that it has enrolled more than 50% of patients in the Company's second pivotal Phase 3 clinical trial (REDUCE 1) evaluating pozdeutinurad (formerly known as AR882) for the reduction of sUA and tophi in gout and tophaceous gout patients.
Read MoreMar 17, 2025
Arthrosi Announces First Patient Dosed in Replicate Pivotal Phase 3 REDUCE 1 Trial of Lead Compound AR882
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced that it has dosed the first patient in REDUCE 1, the Company's second pivotal Phase 3 clinical trial evaluating AR882.
Read MoreMar 05, 2025
Arthrosi Therapeutics Completes Enrollment in Pivotal Phase 3 REDUCE 2 Trial of AR882 for the Treatment of Gout and Tophaceous Gout
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients, today announced the completion of enrollment for its pivotal global Phase 3 REDUCE 2 trial.
Read MoreDec 20, 2024
Arthrosi Therapeutics Surpasses 50% Patient Enrollment in Pivotal Phase 3 REDUCE 2 Trial of AR882 in Patients with Gout, Including Those with Tophaceous Gout
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout, today announced that it has enrolled more than 50% of patients in its pivotal Phase 3 REDUCE 2 trial evaluating AR882 for the reduction of sUA in gout patients.
Read MoreSep 03, 2024
Arthrosi Therapeutics Receives FDA Fast Track Designation for AR882 in Tophaceous Gout
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to treat gout, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AR882 for the potential treatment of clinically visible tophi in patients with gout.
Read MoreJul 01, 2024
Arthrosi Announces First Patient Dosed in Pivotal Phase 3 REDUCE 2 Trial of Lead Compound AR882
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and Tophi in patients with gout, today announced that it has dosed the first patient in REDUCE 2, a pivotal Phase 3 clinical trial to evaluate reduction of sUA in gout patients.
Read More